All In Biotech

Free tool

FAERS Monitor: Livdelzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217899 or its brand name (Livdelzi, Seladelpar Lysine). Reports on generic versions are filed under their own applications.

Reports

276

Serious

101

37% of reports

Hospitalization

17

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective26
  • blood alkaline phosphatase increased24
  • aspartate aminotransferase increased22
  • headache22
  • alanine aminotransferase increased20
  • pruritus20
  • dizziness18
  • fatigue15
  • nausea14
  • diarrhoea12
  • abdominal distension11
  • abdominal pain11
  • hepatic enzyme increased10
  • abdominal pain upper9
  • gamma-glutamyltransferase increased8

Reports by year received

View as table
YearReports
20248
2025157
2026111

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,883 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood alkaline phosphatase increasedSignal2473.850.31,651
aspartate aminotransferase increasedSignal2231.621.1623
gamma-glutamyltransferase increasedSignal827.513.9179
alanine aminotransferase increasedSignal2024.816.3435
hepatic enzyme increasedSignal1011.26.183
abdominal distensionSignal118.04.561
pruritusSignal204.02.642
abdominal painSignal113.62.018
abdominal pain upperSignal93.31.813
dizzinessSignal182.81.819
headacheSignal222.71.822
drug ineffective261.51.04
fatigue151.50.92
diarrhoea121.40.81
nausea141.30.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.